2025 Q3 -tulosraportti
89 päivää sitten
‧42 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
85 435
Myynti
Määrä
86 590
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 600 | - | - | ||
| 1 668 | - | - | ||
| 5 000 | - | - | ||
| 2 829 | - | - | ||
| 72 839 | - | - |
Ylin
0,175VWAP
Alin
0,165VaihtoMäärä
0,8 4 917 915
VWAP
Ylin
0,175Alin
0,165VaihtoMäärä
0,8 4 917 915
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenThe company Grail, which is Immunovia's competitor in the USA, the stock drops 50 % at the opening in the USA.
·2 päivää sitten · MuokattuDon't see Immunovia on the list there Lys51. Maybe because Immunovia is a "single-cancer" test: Grail's sensitivity for pancreatic cancer (pancreatic cancer) is. Do you think that's impressive? : Stage I Sensitivity 61.9% Stage II Sensitivity 60.0% Google's AI overview: "GRAIL's main competitors in the multi-cancer early detection (MCED) liquid biopsy market include Exact Sciences (Cancerguard), Guardant Health, Freenome, and Delfi Diagnostics. These companies are developing blood-based tests, often utilizing AI and next-generation sequencing, to identify early signals of multiple cancers. Key competition focuses on improving stage-one detection sensitivity, reducing costs, and establishing clinical utility for large-scale screening. LinkedIn LinkedIn +4 Exact Sciences (Cancerguard): Launched as a direct, lower-cost competitor to GRAIL's Galleri test. It uses a multiomic approach (methylation and proteins) and claims to potentially improve sensitivity by incorporating DNA variants. Guardant Health: A major competitor specializing in comprehensive genomic profiling and liquid biopsies, often focusing on testing throughout the patient care journey. Freenome: Known for significant funding and a focus on AI-driven multiomic approaches for cancer detection, analyzing both molecular and clinical data. Delfi Diagnostics: Develops cancer detection tests based on fragmentomics (analyzing the pattern of DNA fragments) and is considered a key emerging player. Other Competitors: Adela and Singlera Genomics are also advancing liquid biopsy technologies in the early detection space."- ·3 päivää sittenCompetition. Immunovia vs Oncopeptides. Both stocks down 99 % in 5 years but still alive. Which stock would you bet on???? Starting prices Immunovia 17 öre, Onco 1,70 kr. End date 30th September 2026. Trying to send 1 fl Moet to the winner on the last of September.
- ·3 päivää sittenThe quarterly earnings date is approaching. Isn't it natural for people to position themselves for what it might bring? Stock trading has been rather unchanged in behavior for a very long time with IMMNOV. So if one sees changes before Q4 in the coming days, isn't that a sign of FOMO? I'm waiting in anticipation.
·2 päivää sittenLuckily one has invested in Gold, it compensates for the loss.·2 päivää sittenNow, silver will probably become quite attractive going forward? - ·17.2. · MuokattuPerhaps good without a reverse split? The stock would have fallen anyway these days, I would think. Isn't it better that the stock maintains its price so people don't have to think so hard to see directly how much dilution and selling have affected it? Also seems to be happening completely without short selling?
- ·17.2. · MuokattuPancreaSure vs. Avantect (further, with questions about market success. Also asked AI) : Immunovia is currently closer to direct market presence because they are publicly traded and already have an active commercial rollout for PancreaSure in the U.S. (including recent regulatory approval in California). Market Strategy: They are executing a "Three-Phase Launch." Through mid-2026, they are focusing on Targeted Advocacy (getting the test into top-tier cancer centers). Volume building is expected in late 2026, with meaningful revenue growth projected for 2027. Stock Status: It is a "Penny Stock" on the Stockholm exchange (trading around 0.18 SEK). The Risk/Reward: * The Bull Case: They secured a Medicare reimbursement rate of $897, which is a huge hurdle to clear. If they secure full Medicare coverage in late 2026, the stock could re-rate significantly. The Bear Case: They have a heavy "burn rate" (SEK 8-10M/month) and a cash runway only into Q3 2026. They recently had to withdraw a reverse share split proposal due to shareholder pressure, indicating a volatile relationship with their investor base. ClearNote Health — "The Institutional Favorite" ClearNote is a private, venture-backed company. While they don't offer the daily liquidity of a stock, they are arguably further ahead in clinical "buy-in." Market Strategy: They have a massive strategic partnership with Claritev (formerly MultiPlan), giving them access to national PPO networks. This gives them a "built-in" patient base that Immunovia lacks. The Competitive Moat: They are the clear leader in the New-Onset Diabetes niche. By focusing on a specific, high-risk medical event (new diabetes diagnosis), they have a much clearer path to becoming a "standard of care" compared to Immunovia's broader high-risk focus. IPO Potential: They raised a Series D ($21.8M) in mid-2025. In the private secondary markets, they are valued around $272M. Analysts view them as a prime candidate for a 2026/2027 IPO or a buyout by a giant like Guardant Health or Illumina. The Verdict If you want a "Lotto Ticket": Immunovia is the play. It’s beaten down, but if they survive their cash crunch and get Medicare coverage, the upside from 0.18 SEK is mathematically massive. If you want Stability/Acquisition Potential: Watch for ClearNote's IPO or search for an ETF that holds late-stage biotech (though they are rarely pure-plays).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
89 päivää sitten
‧42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenThe company Grail, which is Immunovia's competitor in the USA, the stock drops 50 % at the opening in the USA.·2 päivää sitten · MuokattuDon't see Immunovia on the list there Lys51. Maybe because Immunovia is a "single-cancer" test: Grail's sensitivity for pancreatic cancer (pancreatic cancer) is. Do you think that's impressive? : Stage I Sensitivity 61.9% Stage II Sensitivity 60.0% Google's AI overview: "GRAIL's main competitors in the multi-cancer early detection (MCED) liquid biopsy market include Exact Sciences (Cancerguard), Guardant Health, Freenome, and Delfi Diagnostics. These companies are developing blood-based tests, often utilizing AI and next-generation sequencing, to identify early signals of multiple cancers. Key competition focuses on improving stage-one detection sensitivity, reducing costs, and establishing clinical utility for large-scale screening. LinkedIn LinkedIn +4 Exact Sciences (Cancerguard): Launched as a direct, lower-cost competitor to GRAIL's Galleri test. It uses a multiomic approach (methylation and proteins) and claims to potentially improve sensitivity by incorporating DNA variants. Guardant Health: A major competitor specializing in comprehensive genomic profiling and liquid biopsies, often focusing on testing throughout the patient care journey. Freenome: Known for significant funding and a focus on AI-driven multiomic approaches for cancer detection, analyzing both molecular and clinical data. Delfi Diagnostics: Develops cancer detection tests based on fragmentomics (analyzing the pattern of DNA fragments) and is considered a key emerging player. Other Competitors: Adela and Singlera Genomics are also advancing liquid biopsy technologies in the early detection space."
- ·3 päivää sittenCompetition. Immunovia vs Oncopeptides. Both stocks down 99 % in 5 years but still alive. Which stock would you bet on???? Starting prices Immunovia 17 öre, Onco 1,70 kr. End date 30th September 2026. Trying to send 1 fl Moet to the winner on the last of September.
- ·3 päivää sittenThe quarterly earnings date is approaching. Isn't it natural for people to position themselves for what it might bring? Stock trading has been rather unchanged in behavior for a very long time with IMMNOV. So if one sees changes before Q4 in the coming days, isn't that a sign of FOMO? I'm waiting in anticipation.·2 päivää sittenLuckily one has invested in Gold, it compensates for the loss.·2 päivää sittenNow, silver will probably become quite attractive going forward?
- ·17.2. · MuokattuPerhaps good without a reverse split? The stock would have fallen anyway these days, I would think. Isn't it better that the stock maintains its price so people don't have to think so hard to see directly how much dilution and selling have affected it? Also seems to be happening completely without short selling?
- ·17.2. · MuokattuPancreaSure vs. Avantect (further, with questions about market success. Also asked AI) : Immunovia is currently closer to direct market presence because they are publicly traded and already have an active commercial rollout for PancreaSure in the U.S. (including recent regulatory approval in California). Market Strategy: They are executing a "Three-Phase Launch." Through mid-2026, they are focusing on Targeted Advocacy (getting the test into top-tier cancer centers). Volume building is expected in late 2026, with meaningful revenue growth projected for 2027. Stock Status: It is a "Penny Stock" on the Stockholm exchange (trading around 0.18 SEK). The Risk/Reward: * The Bull Case: They secured a Medicare reimbursement rate of $897, which is a huge hurdle to clear. If they secure full Medicare coverage in late 2026, the stock could re-rate significantly. The Bear Case: They have a heavy "burn rate" (SEK 8-10M/month) and a cash runway only into Q3 2026. They recently had to withdraw a reverse share split proposal due to shareholder pressure, indicating a volatile relationship with their investor base. ClearNote Health — "The Institutional Favorite" ClearNote is a private, venture-backed company. While they don't offer the daily liquidity of a stock, they are arguably further ahead in clinical "buy-in." Market Strategy: They have a massive strategic partnership with Claritev (formerly MultiPlan), giving them access to national PPO networks. This gives them a "built-in" patient base that Immunovia lacks. The Competitive Moat: They are the clear leader in the New-Onset Diabetes niche. By focusing on a specific, high-risk medical event (new diabetes diagnosis), they have a much clearer path to becoming a "standard of care" compared to Immunovia's broader high-risk focus. IPO Potential: They raised a Series D ($21.8M) in mid-2025. In the private secondary markets, they are valued around $272M. Analysts view them as a prime candidate for a 2026/2027 IPO or a buyout by a giant like Guardant Health or Illumina. The Verdict If you want a "Lotto Ticket": Immunovia is the play. It’s beaten down, but if they survive their cash crunch and get Medicare coverage, the upside from 0.18 SEK is mathematically massive. If you want Stability/Acquisition Potential: Watch for ClearNote's IPO or search for an ETF that holds late-stage biotech (though they are rarely pure-plays).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
85 435
Myynti
Määrä
86 590
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 600 | - | - | ||
| 1 668 | - | - | ||
| 5 000 | - | - | ||
| 2 829 | - | - | ||
| 72 839 | - | - |
Ylin
0,175VWAP
Alin
0,165VaihtoMäärä
0,8 4 917 915
VWAP
Ylin
0,175Alin
0,165VaihtoMäärä
0,8 4 917 915
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
2025 Q3 -tulosraportti
89 päivää sitten
‧42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenThe company Grail, which is Immunovia's competitor in the USA, the stock drops 50 % at the opening in the USA.·2 päivää sitten · MuokattuDon't see Immunovia on the list there Lys51. Maybe because Immunovia is a "single-cancer" test: Grail's sensitivity for pancreatic cancer (pancreatic cancer) is. Do you think that's impressive? : Stage I Sensitivity 61.9% Stage II Sensitivity 60.0% Google's AI overview: "GRAIL's main competitors in the multi-cancer early detection (MCED) liquid biopsy market include Exact Sciences (Cancerguard), Guardant Health, Freenome, and Delfi Diagnostics. These companies are developing blood-based tests, often utilizing AI and next-generation sequencing, to identify early signals of multiple cancers. Key competition focuses on improving stage-one detection sensitivity, reducing costs, and establishing clinical utility for large-scale screening. LinkedIn LinkedIn +4 Exact Sciences (Cancerguard): Launched as a direct, lower-cost competitor to GRAIL's Galleri test. It uses a multiomic approach (methylation and proteins) and claims to potentially improve sensitivity by incorporating DNA variants. Guardant Health: A major competitor specializing in comprehensive genomic profiling and liquid biopsies, often focusing on testing throughout the patient care journey. Freenome: Known for significant funding and a focus on AI-driven multiomic approaches for cancer detection, analyzing both molecular and clinical data. Delfi Diagnostics: Develops cancer detection tests based on fragmentomics (analyzing the pattern of DNA fragments) and is considered a key emerging player. Other Competitors: Adela and Singlera Genomics are also advancing liquid biopsy technologies in the early detection space."
- ·3 päivää sittenCompetition. Immunovia vs Oncopeptides. Both stocks down 99 % in 5 years but still alive. Which stock would you bet on???? Starting prices Immunovia 17 öre, Onco 1,70 kr. End date 30th September 2026. Trying to send 1 fl Moet to the winner on the last of September.
- ·3 päivää sittenThe quarterly earnings date is approaching. Isn't it natural for people to position themselves for what it might bring? Stock trading has been rather unchanged in behavior for a very long time with IMMNOV. So if one sees changes before Q4 in the coming days, isn't that a sign of FOMO? I'm waiting in anticipation.·2 päivää sittenLuckily one has invested in Gold, it compensates for the loss.·2 päivää sittenNow, silver will probably become quite attractive going forward?
- ·17.2. · MuokattuPerhaps good without a reverse split? The stock would have fallen anyway these days, I would think. Isn't it better that the stock maintains its price so people don't have to think so hard to see directly how much dilution and selling have affected it? Also seems to be happening completely without short selling?
- ·17.2. · MuokattuPancreaSure vs. Avantect (further, with questions about market success. Also asked AI) : Immunovia is currently closer to direct market presence because they are publicly traded and already have an active commercial rollout for PancreaSure in the U.S. (including recent regulatory approval in California). Market Strategy: They are executing a "Three-Phase Launch." Through mid-2026, they are focusing on Targeted Advocacy (getting the test into top-tier cancer centers). Volume building is expected in late 2026, with meaningful revenue growth projected for 2027. Stock Status: It is a "Penny Stock" on the Stockholm exchange (trading around 0.18 SEK). The Risk/Reward: * The Bull Case: They secured a Medicare reimbursement rate of $897, which is a huge hurdle to clear. If they secure full Medicare coverage in late 2026, the stock could re-rate significantly. The Bear Case: They have a heavy "burn rate" (SEK 8-10M/month) and a cash runway only into Q3 2026. They recently had to withdraw a reverse share split proposal due to shareholder pressure, indicating a volatile relationship with their investor base. ClearNote Health — "The Institutional Favorite" ClearNote is a private, venture-backed company. While they don't offer the daily liquidity of a stock, they are arguably further ahead in clinical "buy-in." Market Strategy: They have a massive strategic partnership with Claritev (formerly MultiPlan), giving them access to national PPO networks. This gives them a "built-in" patient base that Immunovia lacks. The Competitive Moat: They are the clear leader in the New-Onset Diabetes niche. By focusing on a specific, high-risk medical event (new diabetes diagnosis), they have a much clearer path to becoming a "standard of care" compared to Immunovia's broader high-risk focus. IPO Potential: They raised a Series D ($21.8M) in mid-2025. In the private secondary markets, they are valued around $272M. Analysts view them as a prime candidate for a 2026/2027 IPO or a buyout by a giant like Guardant Health or Illumina. The Verdict If you want a "Lotto Ticket": Immunovia is the play. It’s beaten down, but if they survive their cash crunch and get Medicare coverage, the upside from 0.18 SEK is mathematically massive. If you want Stability/Acquisition Potential: Watch for ClearNote's IPO or search for an ETF that holds late-stage biotech (though they are rarely pure-plays).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
85 435
Myynti
Määrä
86 590
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 600 | - | - | ||
| 1 668 | - | - | ||
| 5 000 | - | - | ||
| 2 829 | - | - | ||
| 72 839 | - | - |
Ylin
0,175VWAP
Alin
0,165VaihtoMäärä
0,8 4 917 915
VWAP
Ylin
0,175Alin
0,165VaihtoMäärä
0,8 4 917 915
Välittäjätilasto
Dataa ei löytynyt